Clinical trial gives women with gene mutation power over disease

September 8, 2023 9:00 am

When Juana Padron, a 40-year-old mother of four, chose to have a genetic test, going against her friends and family’s advice was the last thing on her mind.

Padron’s aunt died from breast cancer, and she watched her sister endure … Read more

New biomarker offers hope for earlier ovarian cancer detection

August 9, 2023 9:00 am

Ovarian cancer is particularly difficult to detect, as the disease often does not produce significant symptoms until it has reached late stages and caused metastasis. New screening methods would help physicians detect ovarian tumors early and dramatically increase the chances … Read more

Protein Discovery Aids Ovarian Cancer Detection

July 7, 2023 9:00 am

In Science Advances, Nagoya University scientists publish their work discovering three membrane proteins associated with ovarian cancer. The research team are hopeful that their discovery could improve approaches for detecting and diagnosing the disease.

Reliable biomarkers lacking for ovarian

Read more

Ovarian Cancer in Black and African American Communities

February 3, 2023 3:10 pm

Ovarian cancer outcomes are less positive for Black and African American persons compared to other communities, but the reasons why are not entirely clear. Anne Mette Buhl, PhD, Director of Science and Clinical Trials, from The Clearity Foundation, recently contributed Read more

Restoring the gut biome after antibiotics could lead to better outcomes for ovarian cancer patients

November 8, 2022 11:09 am

by Cleveland Clinic

Reassessing antibiotic dosage and type could improve survival rates in deadliest gynecologic malignancy, Cleveland Clinic research finds

Newswise — CLEVELAND – Antibiotics routinely used in ovarian cancer care indiscriminately kill gut bacteria, leading to faster cancer progression … Read more

Elizabeth Swisher, MD, on Predicting Therapy Benefits in Ovarian Cancer

October 5, 2022 4:42 pm

by Mark L. Fuerst

– KELIM score can now be used to look at upfront response, study showed

Tumor primary chemosensitivity testing can help determine if ovarian cancer patients need a boost along with first-line chemotherapy. In the VELIA trial, … Read more

Ovarian Cancer Detection Takes a Step Forward

September 12, 2022 1:45 pm

A new type of technology can capture stray ovarian cancer cells from a simple blood test and successfully predict cancer in people who have a lesion or cyst in the pelvic region, according to a new study by a Wilmot … Read more

Epigenetic ‘Priming’ Boosts Cancer Immunotherapy

July 25, 2022 11:11 am

by Will Doss

An epigenetic inhibitor can boost immune system activity in patients with ovarian cancer, making them more suitable for treatment with immunotherapy, according to a Northwestern Medicine study published in the Journal of Clinical Investigation.

This could … Read more

Breast, Ovarian Cancer Study Finds Ties Between Types of BRCA Alterations, Treatment Response

July 7, 2022 10:30 am

NEW YORK – Epigenetic changes to the promoter regions of BRCA1 appear to have a different effect on treatment response than genomic alterations in BRCA1 or BRCA2 in triple-negative breast cancer (TNBC) or ovarian carcinoma patients, new research suggests.

For Read more

MD Anderson Researchers Present Encouraging Results of Early-Stage Clinical Trials at 2022 ASCO Annual Meeting

June 7, 2022 10:45 am

by University of Texas M.D. Anderson Cancer Center

Newswise — CHICAGO ― Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show promising activity with novel immunotherapies and targeted therapies for … Read more

Biomarkers May Identify Ovarian Cancer Patients Who Benefit From AstraZeneca WEE1 Inhibitor

June 5, 2022 9:55 am

by Caroline Hopkins

CHICAGO – AstraZeneca’s investigational WEE1 inhibitor adavosertib showed potential in biomarker-selected advanced ovarian cancer populations in two studies presented during the American Society of Clinical Oncology’s annual meeting Saturday.

The drug, which AstraZeneca licensed from Merck in … Read more

A Sensor Sniffs for Cancer, Using Artificial Intelligence

May 12, 2022 9:51 am

Biomedical engineer Daniel Heller leads the Cancer Nanomedicine Laboratory at MSK. 

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have developed a sensor that can be trained to sniff for cancer, with the help of artificial intelligence.

Although the training … Read more

Navicixizumab Plus Paclitaxel in Platinum-Resistant Ovarian Cancer

April 27, 2022 12:40 pm

by Matthew Stenger

In a phase Ib study reported in the Journal of Clinical Oncology, Fu et al found that the combination of navicixizumab (a bispecific antiangiogenic antibody to VEGF and delta-like ligand 4) and paclitaxel showed activity in … Read more

Biomarkers Found for Platinum Resistance in Gynecologic Cancer

November 19, 2021 11:56 am

Blood-based metabolic signatures may predict whether women with ovarian or uterine cancer will respond well to platinum-based chemotherapy, according to a study by researchers in the Department of Gynecology at the Federal University of São Paulo’s Medical School (EPM-UNIFESP) in … Read more

MCW scientists uncover potential therapeutic target and biomarker for ovarian cancerPortfolio Inspiration

November 17, 2021 11:28 am

MEDICAL COLLEGE OF WISCONSIN

The study’s findings suggest targeting protein FXR1 to inhibit the progression of the cMYC oncogene, a gene mutation often over-expressed in patients with ovarian cancer

Scientists at the Medical College of Wisconsin (MCW) Cancer Center and … Read more

Repare Therapeutics’ RP-3500 Shows Potential of ATR Inhibitors in Precision Oncology

November 4, 2021 11:09 am

by Alison Kanski

NEW YORK – Pharma companies are racing to develop oral ATR inhibitors that present a unique pan-cancer market opportunity.

Researchers reported positive Phase I results on one of these drugs, Repare Therapeutics’ RP3500, last month across tumor … Read more

3 Points: Numbers Have a Different Meaning for Patients With Cancer

October 21, 2021 12:00 am

by Julie S. Brokaw

A woman with ovarian cancer describes how blood work numbers play a key role for patients with cancer and often dictate their thoughts and worries.

The number three is a special number. As a former math

Read more

ARIEL2 Analysis Sheds Light on Biomarkers of Response to Rucaparib in Ovarian Cancer

May 4, 2021 2:00 pm

RAD51C and RAD51D mutations and high-level BRCA1 promotor methylation are predictive of response to rucaparib in patients with recurrent ovarian cancer, while genomic scars linked with homologous recombination deficiency is predictive of response only in those with platinum-sensitive disease.

By … Read more

High Tumor Mutational Burden Predicts Immunotherapy Response in Some—but Not All—Cancers

March 16, 2021 6:00 pm

High tumor mutational burden (TMB) was useful for predicting clinical responses to immune checkpoint inhibitors only in a subset of cancer types, according to a study published by McGrail et al in Annals of Oncology.

The findings suggest that … Read more

Pap Test/Cervical Swab Samples Can Reveal Ovarian Cancer Biomarkers

February 22, 2021 10:00 am

 Sharon Worcester

Residual fixatives from liquid-based Pap tests and cervical swabs contain tumor-specific biomarkers for ovarian cancer, according to an analysis of proteins found in matched biospecimens from a woman with high grade serous ovarian cancer.

The findings suggest … Read more